MCP: This protein makes antibody drugs work
Hundreds of therapeutic antibody drugs target cell-surface molecules in cancers and other diseases. But different patients respond differently to antibody therapy, and doctors struggle to predict who will benefit most.
Except for a few used to ferry drugs or toxins to a specific cell population, most antibodies work by recruiting the immune system. When natural killer cells, the body’s tiny assassins, recognize antibodies coating a target cell, the NK cells latch onto the target and kill it.
Kashyap Patel, a grad student at Iowa State University, studies the receptor CD16a, receptor protein on natural killer cells that recognizes and binds to antibodies. Patel and his advisor, Adam Barb, now a professor at the University of Georgia, were interested in changes to CD16a that might underlie binding changes.
“CD16a in our bodies is different than the CD16a that’s used to test monoclonal antibodies,” Patel said. Whereas the recombinant version used in laboratories has limited posttranslational modifications, the human version is glycosylated at five different sites. Glycosylation, which happens in the endoplasmic reticulum, can add complex branched structures to a protein; those modifications can alter proteins’ binding characteristics and could in principle make CD16a more or less likely to bind to antibodies.
Scientists know that a genetic polymorphism near one N-glycosylation site in CD16a can influence how well antibody treatment works. It isn’t clear whether that polymorphism affects glycans directly or whether genetic changes that do affect glycans affect CD16a-antibody binding. Studying the variations in glycan structure at each site is difficult, because isolating enough CD16a from a single person to analyze poses a technical challenge.
In a recent article in the journal Molecular & Cellular Proteomics, Patel, Barb and colleagues report that they studied post-translational modifications to CD16a in glycopeptide samples harvested from the natural killer cells of individual plasma donors. Then they used glycomics tools to determine the structures of the glycans.
“We weren’t expecting the variability we saw,” Patel said. At five sites in CD16a, the team found substantial variability in the structure of glycans — both among the donors and within each individual.
The researchers don’t know yet what to make of the glycan variability, because the donor pool was small and few studies of this type have been done. However, now that the protocol for studying glycan composition from a single person is worked out, Barb’s lab hopes to determine whether changes to that composition affect the immune system’s response to antibody therapy.
When Patel started this project, he didn’t know much about protein glycosylation, but he said he intends to keep studying it as a postdoctoral fellow.
“Once you see a protein with N-glycans on it, you cannot unsee it. You can’t ignore it.”
Join the ASBMB Today mailing list
Sign up to get updates on articles, interviews and events.
Despite the recent approval of this drug for use against COVID-19, questions remain as to the efficacy of this treatment.
In the inaugural JBC Methods Madness Tournament, cryo–EM/ET gave structural biologists around the world something to cheer about, beating mass spectrometry 51% to 49% — a margin thinner than shaved ice.
Scientists at eight institutions in the U.S. and Europe have used a protein interaction map to identify 69 drugs that might work against SARS-CoV-2, the virus that causes COVID-19.